Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?

Sara De Carolis; Angela Botta; Arsene Mekinian; Nathalie Costedoat-Chalumeau; Agathe Masseau; Angela Tincani; Jaume Alijotas-Reig; Ales Ambrozic; Véronique Le Guern; Ruth Fritsch-Stork; Pascale Nicaise-Roland; Bruno Carbonne; Lionel Carbillon; Olivier Fain

doi:10.1016/j.autrev.2014.08.040

Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?

Sara De Carolis, Angela Botta, Arsene Mekinian, Nathalie Costedoat-Chalumeau, Agathe Masseau, Angela Tincani, Jaume Alijotas-Reig, Ales Ambrozic, Véronique Le Guern, Ruth Fritsch-Stork, Pascale Nicaise-Roland, Bruno Carbonne, Lionel Carbillon, Olivier Fain

Risultato della ricerca: Contributo in rivista › Articolo in rivista

43 Citazioni (Scopus)

Abstract

The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH) dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The persistence of adverse pregnancy outcome raises the need to find other drugs to improve obstetrical outcome. Hydroxychloroquine is widely used in patients with various autoimmune diseases, particularly SLE. Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen-antibody reactions. There is ample evidence of protective effects of hydroxychloroquine in OAPS similar to the situation in SLE arising from in vitro studies of pathophysiological working mechanism of hydroxychloroquine. However, the clinical data on the use of hydroxychloroquine in primary APS are lacking and prospective studies are necessary.

Lingua originale	English
pagine (da-a)	23-29
Numero di pagine	7
Rivista	AUTOIMMUNITY REVIEWS
Volume	14
DOI	https://doi.org/10.1016/j.autrev.2014.08.040
Stato di pubblicazione	Pubblicato - 2015

Keywords

Anti-Inflammatory Agents
Antiphospholipid Syndrome
Antiphospholipid syndrome
Female
Humans
Hydroxychloroquine
Outcome
Pregnancy
Pregnancy Complications
Pregnancy Outcome
Prognosis

Accesso al documento

10.1016/j.autrev.2014.08.040

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

De Carolis, S., Botta, A., Mekinian, A., Costedoat-Chalumeau, N., Masseau, A., Tincani, A., Alijotas-Reig, J., Ambrozic, A., Le Guern, V., Fritsch-Stork, R., Nicaise-Roland, P., Carbonne, B., Carbillon, L., & Fain, O. (2015). Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? AUTOIMMUNITY REVIEWS, 14, 23-29. https://doi.org/10.1016/j.autrev.2014.08.040

De Carolis, Sara ; Botta, Angela ; Mekinian, Arsene ; Costedoat-Chalumeau, Nathalie ; Masseau, Agathe ; Tincani, Angela ; Alijotas-Reig, Jaume ; Ambrozic, Ales ; Le Guern, Véronique ; Fritsch-Stork, Ruth ; Nicaise-Roland, Pascale ; Carbonne, Bruno ; Carbillon, Lionel ; Fain, Olivier. / Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?. In: AUTOIMMUNITY REVIEWS. 2015 ; Vol. 14. pagg. 23-29.

@article{515840bb7776490d86874c5c1cf7afa6,

title = "Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?",

abstract = "The use of the conventional APS treatment (the combination of low-dose aspirin and LMWH) dramatically improved the obstetrical prognosis in primary obstetrical APS (OAPS). The persistence of adverse pregnancy outcome raises the need to find other drugs to improve obstetrical outcome. Hydroxychloroquine is widely used in patients with various autoimmune diseases, particularly SLE. Antimalarials have many anti-inflammatory, anti-aggregant and immune-regulatory properties: they inhibit phospholipase activity, stabilize lysosomal membranes, block the production of several pro-inflammatory cytokines and, in addition, impair complement-dependent antigen-antibody reactions. There is ample evidence of protective effects of hydroxychloroquine in OAPS similar to the situation in SLE arising from in vitro studies of pathophysiological working mechanism of hydroxychloroquine. However, the clinical data on the use of hydroxychloroquine in primary APS are lacking and prospective studies are necessary.",

keywords = "Anti-Inflammatory Agents, Antiphospholipid Syndrome, Antiphospholipid syndrome, Female, Humans, Hydroxychloroquine, Outcome, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Prognosis, Anti-Inflammatory Agents, Antiphospholipid Syndrome, Antiphospholipid syndrome, Female, Humans, Hydroxychloroquine, Outcome, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Prognosis",

author = "{De Carolis}, Sara and Angela Botta and Arsene Mekinian and Nathalie Costedoat-Chalumeau and Agathe Masseau and Angela Tincani and Jaume Alijotas-Reig and Ales Ambrozic and {Le Guern}, V{\'e}ronique and Ruth Fritsch-Stork and Pascale Nicaise-Roland and Bruno Carbonne and Lionel Carbillon and Olivier Fain",

year = "2015",

doi = "10.1016/j.autrev.2014.08.040",

language = "English",

volume = "14",

pages = "23--29",

journal = "AUTOIMMUNITY REVIEWS",

issn = "1873-0183",

publisher = "New York : Elsevier Science",

}

De Carolis, S, Botta, A, Mekinian, A, Costedoat-Chalumeau, N, Masseau, A, Tincani, A, Alijotas-Reig, J, Ambrozic, A, Le Guern, V, Fritsch-Stork, R, Nicaise-Roland, P, Carbonne, B, Carbillon, L & Fain, O 2015, 'Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?', AUTOIMMUNITY REVIEWS, vol. 14, pagg. 23-29. https://doi.org/10.1016/j.autrev.2014.08.040

Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? / De Carolis, Sara; Botta, Angela; Mekinian, Arsene; Costedoat-Chalumeau, Nathalie; Masseau, Agathe; Tincani, Angela; Alijotas-Reig, Jaume; Ambrozic, Ales; Le Guern, Véronique; Fritsch-Stork, Ruth; Nicaise-Roland, Pascale; Carbonne, Bruno; Carbillon, Lionel; Fain, Olivier.